Acumen Pharmaceuticals, INC. 8-K Filing
Ticker: ABOS · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1576885
| Field | Detail |
|---|---|
| Company | Acumen Pharmaceuticals, INC. (ABOS) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000, $30,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Acumen Pharmaceuticals, INC. (ticker: ABOS) to the SEC on Nov 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ge on which registered Common Stock, $0.0001 par value ABOS The Nasdaq Global Select); $40,000 (olumbeski will be entitled to receive a $40,000 annual retainer for his service on the); $30,000 (iner for his service on the Board and a $30,000 annual retainer for his service as Chai).
How long is this filing?
Acumen Pharmaceuticals, INC.'s 8-K filing is 4 pages with approximately 1,102 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,102 words · 4 min read · ~4 pages · Grade level 10.4 · Accepted 2025-11-10 08:25:49
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value ABOS The Nasdaq Global Select
- $40,000 — olumbeski will be entitled to receive a $40,000 annual retainer for his service on the
- $30,000 — iner for his service on the Board and a $30,000 annual retainer for his service as Chai
Filing Documents
- abos-20251106.htm (8-K) — 32KB
- ex-991acumenpharmaceutic.htm (EX-99.1) — 8KB
- ex-991acumenpharmaceutic001.jpg (GRAPHIC) — 207KB
- ex-991acumenpharmaceutic002.jpg (GRAPHIC) — 234KB
- ex-991acumenpharmaceutic003.jpg (GRAPHIC) — 135KB
- 0001628280-25-050800.txt ( ) — 961KB
- abos-20251106.xsd (EX-101.SCH) — 2KB
- abos-20251106_lab.xml (EX-101.LAB) — 23KB
- abos-20251106_pre.xml (EX-101.PRE) — 13KB
- abos-20251106_htm.xml (XML) — 3KB
02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On November 6, 2025, the Board of Directors (the " Board ") of Acumen Pharmaceuticals, Inc. (the " Company ") approved the appointment of Dr. George Golumbeski to serve as a director of the Board, effective November 6, 2025 (the " Effective Date "). Dr. Golumbeski has been designated a Class II director to hold office until the Company's 2026 Annual Meeting of Stockholders, or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Dr. Golumbeski is "independent" pursuant to the rules of The Nasdaq Stock Market LLC and other governing laws and applicable regulations. In addition, Dr. Golumbeski has also been appointed to replace Dr. Sean Stalfort as Chairman of the Board. Dr. Golumbeski has served as a partner at DROIA Ventures, a venture capital firm focused on therapeutics for oncology and genetic disease, since October 2020 and previously served as the President and Head of Corporate Development for GRAIL, Inc. from August 2018 to September 2019. From 2009 to April 2018, Dr. Golumbeski served as Executive Vice President of Business Development for Celgene Corporation (" Celgene "). Prior to Celgene, Dr. Golumbeski was Vice President of Business Development, Licensing, and Strategy at Novartis. Dr. Golumbeski has served on the board of Shattuck Labs, Inc. since January 2018, and he serves on the boards of directors of various private companies. He also previously served on the boards of directors of Sage Therapeutics, Inc., MorphoSys AG and Enanta Pharmaceuticals, Inc. Dr. Golumbeski received a B.A. in Biology from the University of Virginia and a Ph.D. in genetics from the University of Wisconsin—Madison. The Board believes Dr. Golumbeski is qualified to serve as a director based on his significant experience in research and development, business development and lea
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 10, 2025, the Company issued a press release announcing the appointment of Dr. Golumbeski as a director of the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing, except as otherwise expressly stated in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Press Release, dated November 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acumen Pharmaceuticals, Inc. Dated: November 10, 2025 By: /s/ Derek Meisner Derek Meisner Chief Legal Officer